These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

2381 related items for PubMed ID: 24933658

  • 21. Allogeneic hematopoietic stem-cell transplantation for acute myeloid leukemia in remission: comparison of intravenous busulfan plus cyclophosphamide (Cy) versus total-body irradiation plus Cy as conditioning regimen--a report from the acute leukemia working party of the European group for blood and marrow transplantation.
    Nagler A, Rocha V, Labopin M, Unal A, Ben Othman T, Campos A, Volin L, Poire X, Aljurf M, Masszi T, Socie G, Sengelov H, Michallet M, Passweg J, Veelken H, Yakoub-Agha I, Shimoni A, Mohty M.
    J Clin Oncol; 2013 Oct 01; 31(28):3549-56. PubMed ID: 23980086
    [Abstract] [Full Text] [Related]

  • 22. Unrelated cord blood compared with haploidentical grafts in patients with hematological malignancies.
    El-Cheikh J, Crocchiolo R, Furst S, Bramanti S, Sarina B, Granata A, Vai A, Lemarie C, Faucher C, Mohty B, Harbi S, Bouabdallah R, Vey N, Santoro A, Chabannon C, Castagna L, Blaise D.
    Cancer; 2015 Jun 01; 121(11):1809-16. PubMed ID: 25649994
    [Abstract] [Full Text] [Related]

  • 23. Impact of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation for acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European group for blood and marrow transplantation.
    Baron F, Labopin M, Niederwieser D, Vigouroux S, Cornelissen JJ, Malm C, Vindelov LL, Blaise D, Janssen JJ, Petersen E, Socié G, Nagler A, Rocha V, Mohty M.
    Leukemia; 2012 Dec 01; 26(12):2462-8. PubMed ID: 22699419
    [Abstract] [Full Text] [Related]

  • 24. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival.
    Valcárcel D, Martino R, Caballero D, Martin J, Ferra C, Nieto JB, Sampol A, Bernal MT, Piñana JL, Vazquez L, Ribera JM, Besalduch J, Moraleda JM, Carrera D, Brunet MS, Perez-Simón JA, Sierra J.
    J Clin Oncol; 2008 Feb 01; 26(4):577-84. PubMed ID: 18086801
    [Abstract] [Full Text] [Related]

  • 25. Comparison of allogeneic stem cell transplantation from familial-mismatched/haploidentical donors and from unrelated donors in adults with high-risk acute myelogenous leukemia.
    Cho BS, Yoon JH, Shin SH, Yahng SA, Lee SE, Eom KS, Kim YJ, Lee S, Min CK, Cho SG, Kim DW, Lee JW, Min WS, Park CW, Kim HJ.
    Biol Blood Marrow Transplant; 2012 Oct 01; 18(10):1552-63. PubMed ID: 22516055
    [Abstract] [Full Text] [Related]

  • 26. A well-tolerated regimen of 800 cGy TBI-fludarabine-busulfan-ATG for reliable engraftment after unmanipulated haploidentical peripheral blood stem cell transplantation in adult patients with acute myeloid leukemia.
    Yahng SA, Kim JH, Jeon YW, Yoon JH, Shin SH, Lee SE, Cho BS, Eom KS, Kim YJ, Lee S, Min CK, Cho SG, Kim DW, Lee JW, Min WS, Park CW, Kim HJ.
    Biol Blood Marrow Transplant; 2015 Jan 01; 21(1):119-29. PubMed ID: 25300871
    [Abstract] [Full Text] [Related]

  • 27. Unrelated cord blood transplantation for adult patients with acute myeloid leukemia: higher incidence of acute graft-versus-host disease and lower survival in male patients transplanted with female unrelated cord blood--a report from Eurocord, the Acute Leukemia Working Party, and the Cord Blood Committee of the Cellular Therapy and Immunobiology Working Party of the European Group for Blood and Marrow Transplantation.
    Baron F, Labopin M, Ruggeri A, Mohty M, Sanz G, Milpied N, Bacigalupo A, Rambaldi A, Bonifazi F, Bosi A, Sierra J, Yakoub-Agha I, Santasusana JM, Gluckman E, Nagler A.
    J Hematol Oncol; 2015 Oct 06; 8():107. PubMed ID: 26445106
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. [Allogeneic hematopoietic stem cell transplantation for acute myeloblastic leukemia in first remission].
    Bondarenko SN, Semenova EV, Vavilov VN, Stancheva NV, Morozova EV, Alianskiĭ AL, Babenko EV, Osipova NÉ, Zubarovskaia LS, Afanas'ev BV.
    Ter Arkh; 2013 Oct 06; 85(7):18-25. PubMed ID: 24137943
    [Abstract] [Full Text] [Related]

  • 31. Umbilical Cord Blood Transplantation without Antithymocyte Globulin Results in Similar Survival but Better Quality of Life Compared with Unrelated Peripheral Blood Stem Cell Transplantation for the Treatment of Acute Leukemia-A Retrospective Study in China.
    Tong J, Xuan L, Sun Y, Huang D, Liu H, Zheng C, Zhu X, Tang B, Song K, Zhang X, Zhang L, Yao W, Lin D, Liu Q, Sun Z.
    Biol Blood Marrow Transplant; 2017 Sep 06; 23(9):1541-1548. PubMed ID: 28499936
    [Abstract] [Full Text] [Related]

  • 32. Reduced-Intensity Allogeneic Transplant for Acute Myeloid Leukemia and Myelodysplastic Syndrome Using Combined CD34-Selected Haploidentical Graft and a Single Umbilical Cord Unit Compared with Matched Unrelated Donor Stem Cells in Older Adults.
    Tsai SB, Rhodes J, Liu H, Shore T, Bishop M, Cushing MM, Gergis U, Godley L, Kline J, Larson RA, Mayer S, Odenike O, Stock W, Wickrema A, van Besien K, Artz AS.
    Biol Blood Marrow Transplant; 2018 May 06; 24(5):997-1004. PubMed ID: 29288821
    [Abstract] [Full Text] [Related]

  • 33. Comparable Outcomes After Alternative and Matched Sibling Donor Hematopoietic Stem Cell Transplantation and the Role of Molecular Measurable Residual Disease for Acute Myeloid Leukemia in Elderly Patients.
    Cho BS, Yahng SA, Min GJ, Park S, Park SS, Shin SH, Jeon YW, Yoon JH, Lee SE, Eom KS, Kim YJ, Lee S, Min CK, Cho SG, Kim DW, Lee JW, Kim M, Kim Y, Kim HJ.
    Transplant Cell Ther; 2021 Sep 06; 27(9):774.e1-774.e12. PubMed ID: 34082159
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Hematopoietic cell transplantation for mucopolysaccharidosis patients is safe and effective: results after implementation of international guidelines.
    Aldenhoven M, Jones SA, Bonney D, Borrill RE, Coussons M, Mercer J, Bierings MB, Versluys B, van Hasselt PM, Wijburg FA, van der Ploeg AT, Wynn RF, Boelens JJ.
    Biol Blood Marrow Transplant; 2015 Jun 06; 21(6):1106-9. PubMed ID: 25708213
    [Abstract] [Full Text] [Related]

  • 38. The long-term outcome of reduced-intensity allogeneic stem cell transplantation from a matched related or unrelated donor, or haploidentical family donor in patients with leukemia: a retrospective analysis of data from the China RIC Cooperative Group.
    Yu CL, Zheng-Dong, Qiao ZH, Wang JM, Huang-He, Liang YM, Wu DP, Chen BA, Bai-Hai, Shi BF, Sun WJ, Qiao JX, Guo M, Qiao JH, Sun QY, Hu KX, Huang YJ, Zuo HL, Huang XJ, Ai HS.
    Ann Hematol; 2017 Feb 06; 96(2):279-288. PubMed ID: 27864604
    [Abstract] [Full Text] [Related]

  • 39. Unmanipulated haploidentical in comparison with matched unrelated donor stem cell transplantation in patients 60 years and older with acute myeloid leukemia: a comparative study on behalf of the ALWP of the EBMT.
    Santoro N, Labopin M, Giannotti F, Ehninger G, Niederwieser D, Brecht A, Stelljes M, Kröger N, Einsele H, Eder M, Hallek M, Glass B, Finke J, Ciceri F, Mohty M, Ruggeri A, Nagler A.
    J Hematol Oncol; 2018 Apr 16; 11(1):55. PubMed ID: 29661208
    [Abstract] [Full Text] [Related]

  • 40. Allogeneic hematopoietic cell transplantation outcomes in acute myeloid leukemia: similar outcomes regardless of donor type.
    Warlick ED, Peffault de Latour R, Shanley R, Robin M, Bejanyan N, Xhaard A, Brunstein C, Sicre de Fontbrune F, Ustun C, Weisdorf DJ, Socie G.
    Biol Blood Marrow Transplant; 2015 Feb 16; 21(2):357-63. PubMed ID: 25452032
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 120.